N(6)-cyclopentyladenosine

Also Known As:

N6-cyclopentyladenosine

Networked: 59 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        N(6)-cyclopentyladenosine: 59
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - N(6)-cyclopentyladenosine: 59
  - Ribonucleosides: 49
    - Adenosine: 12431
      - N(6)-cyclopentyladenosine: 59

Experts

1.	Herrero, Juan F: 3 articles (08/2013 - 08/2005)
2.	Dickenson, John M: 2 articles (01/2018 - 09/2009)
3.	Hsieh, Ching-Liang: 2 articles (11/2017 - 01/2017)
4.	Huang, Chun-Ping: 2 articles (11/2017 - 01/2017)
5.	Liao, Hsien-Yin: 2 articles (11/2017 - 01/2017)
6.	Lin, Yi-Wen: 2 articles (11/2017 - 01/2017)
7.	Ramos-Zepeda, Guillermo: 2 articles (08/2013 - 08/2005)
8.	Spina, Domenico: 2 articles (12/2011 - 04/2006)
9.	Nelson, Carl P: 1 article (01/2018)
10.	Vyas, Falguni S: 1 article (01/2018)

Related Diseases

1.	Poisoning 04/01/2005 - "[Therapeutic efficacy of N6-cyclopentyladenosine against acute dichlorvos poisoning]." 04/01/2005 - "To study the therapeutic efficacy and mechanism of adenosine receptor agonist N(6)-cyclopentyladenosine (CPA) against acute dichlorvos poisoning. " 01/01/2004 - "Cardiovascular effects of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) decisive for its therapeutic efficacy in sarin poisoning." 07/01/2006 - "Therapy with N(6)-cyclopentyladenosine (CPA), physostigmine, hyoscine and HI-6 protected guinea-pigs against the incapacitating and lethal effects of a supralethal challenge of soman (135 microg/kg) when given 1 min after poisoning. "
2.	Bradycardia 11/30/1993 - "Pertussis toxin pretreatment essentially abolished the bradycardia induced by the prototype A1 receptor agonist, N6-cyclopentyladenosine, whereas the fall in blood pressure induced by the selective A2A receptor agonist, CGS 21680 was enhanced. " 02/01/1993 - "The cardiovascular effects of N6-cyclopentyladenosine (CPA), a selective adenosine A1 receptor agonist and 2-[p-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS 21,680), a selective A2 receptor agonist have been investigated in the pithed rat with blood pressure raised to normal levels with angiotensin II. Cumulative intravenous administration of CPA, 0.3-10 micrograms/kg, induced dose-related falls in blood pressure and heart rate; over the same dose range CGS 21,680 induced hypotension but no bradycardia. " 06/01/1999 - "This improved side effect profile contrasts markedly with the profound hypotension, bradycardia, and hypothermia and greater inhibition of motor function observed with the adenosine receptor agonist N6-cyclopentyladenosine and opens the way to clinical evaluation of AK inhibitors as a novel, adenosine-based approach to anticonvulsant therapy." 07/01/1996 - "The results showed that (1) adenosine and 2-chloroadenosine could induce an initial increase in MAP mediated by the adenosine A2 receptors in carotid body chemoreceptor, and a subsequent decrease in MAP, being attributed to the adenosine A1 receptors in heart and A2 receptors in blood vessels; (2) N6-cyclopentyladenosine (CPA, a selective adenosine A1 receptor agonist) inhibited the electrophysiological activity of pacemaker cells in sinoatrial node; (3) CPA markedly attenuated the development of early afterdepolarization, delayed afterdepolarization and triggered activity induced by isoproterenol; (4) endogenous adenosine might play an important role in the generation of anoxic bradycardia; (5) activation of adenosine receptors along with an increase in adenosine receptor density during the course of ischemic preconditioning might provide the protective effect on the ischemic heart injury; (6) the cardiovascular effects of adenosine and its analogues were mainly mediated by activation of ATP sensitive K+ channels coupled to adenosine receptors."
3.	Hypothermia 01/01/2017 - "Commonly used, selective A1AR agonists, including N6-cyclopentyladenosine (CPA), N6-cyclohexyladenosine (CHA), and MRS5474, caused hypothermia via both A1AR and A3AR when given intraperitoneally. " 07/01/1999 - "We conclude that: (1) effective mutual synchronization with minimal fluctuation happens within the sino-atrial node of intact rat hearts at body temperature, and synchronization is not affected even by extreme changes in pre- and afterload, (2) the sino-atrial node is the sole source of BI variability in the intact isolated rat heart, (3) low temperature hampers this functional organization which can be reestablished by sinus node accelerating agents (isoprenaline, theophylline), (4) decreasing frequency by N6-Cyclopentyladenosine at normothermia also increases BI variability but less pronouncedly than hypothermia does." 06/01/1999 - "This improved side effect profile contrasts markedly with the profound hypotension, bradycardia, and hypothermia and greater inhibition of motor function observed with the adenosine receptor agonist N6-cyclopentyladenosine and opens the way to clinical evaluation of AK inhibitors as a novel, adenosine-based approach to anticonvulsant therapy."
4.	Inflammation (Inflammations) 08/14/2013 - "We previously observed that the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) is a very effective antinociceptive agent on intact but not on spinalized adult rats with inflammation. " 08/12/2005 - "The adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) is very effective in reducing wind-up in intact but not in spinalized adult rats with carrageenan-induced inflammation, suggesting an adenosine-mediated supraspinal modulation. "
5.	Hypotension (Low Blood Pressure) 06/01/1999 - "This improved side effect profile contrasts markedly with the profound hypotension, bradycardia, and hypothermia and greater inhibition of motor function observed with the adenosine receptor agonist N6-cyclopentyladenosine and opens the way to clinical evaluation of AK inhibitors as a novel, adenosine-based approach to anticonvulsant therapy."

Related Drugs and Biologics

1.	Purinergic P1 Receptors (Adenosine Receptor)
2.	Adenosine (Adenocard)
3.	Adenosine A1 Receptor
4.	Dichlorvos
5.	Sarin
6.	Carrageenan
7.	Anticonvulsants (Antiepileptic Drugs)
8.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
9.	N(6)-cyclohexyladenosine
10.	Formaldehyde (Formol)

Related Therapies and Procedures

1.	Therapeutics
2.	Analgesia
3.	Intravenous Administration
4.	Controlled Hypotension